 | • レポートコード：MRC2-11QY08111 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経内分泌がん治療薬のグローバル市場について調査・分析したレポートです。種類別（ソマトスタチン類似体、標的療法、化学療法）市場規模、用途別（病院、診療所、腫瘍学センター、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経内分泌がん治療薬の競争状況、市場シェア ・世界の神経内分泌がん治療薬市場：種類別市場規模 2015年-2020年（ソマトスタチン類似体、標的療法、化学療法） ・世界の神経内分泌がん治療薬市場：種類別市場規模予測 2021年-2026年（ソマトスタチン類似体、標的療法、化学療法） ・世界の神経内分泌がん治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、腫瘍学センター、外来手術センター） ・世界の神経内分泌がん治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、腫瘍学センター、外来手術センター） ・北米の神経内分泌がん治療薬市場分析：米国、カナダ ・ヨーロッパの神経内分泌がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経内分泌がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経内分泌がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経内分泌がん治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Xiaflex、Novartis AG、Roche、Molecular Insight pharmaceuticals、Callisto Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Neuroendocrine Carcinoma Drugs Market
The global Neuroendocrine Carcinoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neuroendocrine Carcinoma Drugs Scope and Market Size
Neuroendocrine Carcinoma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Carcinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neuroendocrine Carcinoma Drugs market is segmented into
Somatostatin Analogs
Targeted Therapy
Chemotherapy
Segment by Application, the Neuroendocrine Carcinoma Drugs market is segmented into
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
Regional and Country-level Analysis
The Neuroendocrine Carcinoma Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuroendocrine Carcinoma Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neuroendocrine Carcinoma Drugs Market Share Analysis
Neuroendocrine Carcinoma Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuroendocrine Carcinoma Drugs business, the date to enter into the Neuroendocrine Carcinoma Drugs market, Neuroendocrine Carcinoma Drugs product introduction, recent developments, etc.
The major vendors covered:
Xiaflex
Novartis AG
Roche
Molecular Insight pharmaceuticals
Callisto Pharmaceuticals
…
1 Study Coverage
1.1 Neuroendocrine Carcinoma Drugs Product Introduction
1.2 Market Segments
1.3 Key Neuroendocrine Carcinoma Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Type
1.4.2 Somatostatin Analogs
1.4.3 Targeted Therapy
1.4.4 Chemotherapy
1.5 Market by Application
1.5.1 Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Oncology Centres
1.5.5 Ambulatory Surgery Centres
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Carcinoma Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neuroendocrine Carcinoma Drugs Revenue 2015-2026
2.1.2 Global Neuroendocrine Carcinoma Drugs Sales 2015-2026
2.2 Global Neuroendocrine Carcinoma Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neuroendocrine Carcinoma Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neuroendocrine Carcinoma Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neuroendocrine Carcinoma Drugs Competitor Landscape by Players
3.1 Neuroendocrine Carcinoma Drugs Sales by Manufacturers
3.1.1 Neuroendocrine Carcinoma Drugs Sales by Manufacturers (2015-2020)
3.1.2 Neuroendocrine Carcinoma Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Neuroendocrine Carcinoma Drugs Revenue by Manufacturers
3.2.1 Neuroendocrine Carcinoma Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Drugs Revenue in 2019
3.2.5 Global Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neuroendocrine Carcinoma Drugs Price by Manufacturers
3.4 Neuroendocrine Carcinoma Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Carcinoma Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Carcinoma Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuroendocrine Carcinoma Drugs Market Size by Type (2015-2020)
4.1.1 Global Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020)
4.1.2 Global Neuroendocrine Carcinoma Drugs Revenue by Type (2015-2020)
4.1.3 Neuroendocrine Carcinoma Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuroendocrine Carcinoma Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neuroendocrine Carcinoma Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuroendocrine Carcinoma Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neuroendocrine Carcinoma Drugs Market Size by Application (2015-2020)
5.1.1 Global Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020)
5.1.2 Global Neuroendocrine Carcinoma Drugs Revenue by Application (2015-2020)
5.1.3 Neuroendocrine Carcinoma Drugs Price by Application (2015-2020)
5.2 Neuroendocrine Carcinoma Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Carcinoma Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neuroendocrine Carcinoma Drugs by Country
6.1.1 North America Neuroendocrine Carcinoma Drugs Sales by Country
6.1.2 North America Neuroendocrine Carcinoma Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Type
6.3 North America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Neuroendocrine Carcinoma Drugs by Country
7.1.1 Europe Neuroendocrine Carcinoma Drugs Sales by Country
7.1.2 Europe Neuroendocrine Carcinoma Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuroendocrine Carcinoma Drugs Market Facts & Figures by Type
7.3 Europe Neuroendocrine Carcinoma Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Carcinoma Drugs by Region
8.1.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Region
8.1.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neuroendocrine Carcinoma Drugs Market Facts & Figures by Type
8.3 Asia Pacific Neuroendocrine Carcinoma Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Drugs by Country
9.1.1 Latin America Neuroendocrine Carcinoma Drugs Sales by Country
9.1.2 Latin America Neuroendocrine Carcinoma Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Type
9.3 Central & South America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Carcinoma Drugs by Country
10.1.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country
10.1.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Description and Business Overview
11.1.3 Xiaflex Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Products Offered
11.1.5 Xiaflex Related Developments
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Description and Business Overview
11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis AG Neuroendocrine Carcinoma Drugs Products Offered
11.2.5 Novartis AG Related Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description and Business Overview
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Neuroendocrine Carcinoma Drugs Products Offered
11.3.5 Roche Related Developments
11.4 Molecular Insight pharmaceuticals
11.4.1 Molecular Insight pharmaceuticals Corporation Information
11.4.2 Molecular Insight pharmaceuticals Description and Business Overview
11.4.3 Molecular Insight pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Products Offered
11.4.5 Molecular Insight pharmaceuticals Related Developments
11.5 Callisto Pharmaceuticals
11.5.1 Callisto Pharmaceuticals Corporation Information
11.5.2 Callisto Pharmaceuticals Description and Business Overview
11.5.3 Callisto Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Products Offered
11.5.5 Callisto Pharmaceuticals Related Developments
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Description and Business Overview
11.1.3 Xiaflex Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Products Offered
11.1.5 Xiaflex Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neuroendocrine Carcinoma Drugs Market Estimates and Projections by Region
12.1.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Neuroendocrine Carcinoma Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
12.2.2 North America: Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Neuroendocrine Carcinoma Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neuroendocrine Carcinoma Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neuroendocrine Carcinoma Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Neuroendocrine Carcinoma Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neuroendocrine Carcinoma Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Carcinoma Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Neuroendocrine Carcinoma Drugs Market Segments
Table 2. Ranking of Global Top Neuroendocrine Carcinoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Somatostatin Analogs
Table 5. Major Manufacturers of Targeted Therapy
Table 6. Major Manufacturers of Chemotherapy
Table 7. Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 8. Global Neuroendocrine Carcinoma Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 9. Global Neuroendocrine Carcinoma Drugs Sales by Regions 2015-2020 (K MT)
Table 10. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Neuroendocrine Carcinoma Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Neuroendocrine Carcinoma Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 13. Global Neuroendocrine Carcinoma Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Neuroendocrine Carcinoma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Neuroendocrine Carcinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2019)
Table 16. Neuroendocrine Carcinoma Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Neuroendocrine Carcinoma Drugs Price (2015-2020) (USD/MT)
Table 19. Neuroendocrine Carcinoma Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Neuroendocrine Carcinoma Drugs Product Type
Table 21. Date of International Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 24. Global Neuroendocrine Carcinoma Drugs Sales Share by Type (2015-2020)
Table 25. Global Neuroendocrine Carcinoma Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Neuroendocrine Carcinoma Drugs Revenue Share by Type (2015-2020)
Table 27. Neuroendocrine Carcinoma Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 28. Global Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 29. Global Neuroendocrine Carcinoma Drugs Sales Share by Application (2015-2020)
Table 30. North America Neuroendocrine Carcinoma Drugs Sales by Country (2015-2020) (K MT)
Table 31. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Neuroendocrine Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 35. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 37. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Neuroendocrine Carcinoma Drugs Sales by Country (2015-2020) (K MT)
Table 39. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Neuroendocrine Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 43. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 45. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Region (2015-2020) (K MT)
Table 47. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 51. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 53. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Neuroendocrine Carcinoma Drugs Sales by Country (2015-2020) (K MT)
Table 55. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Neuroendocrine Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 59. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 61. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country (2015-2020) (K MT)
Table 63. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Type (2015-2020) (K MT)
Table 67. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Application (2015-2020) (K MT)
Table 69. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 70. Xiaflex Corporation Information
Table 71. Xiaflex Description and Major Businesses
Table 72. Xiaflex Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 73. Xiaflex Product
Table 74. Xiaflex Recent Development
Table 75. Novartis AG Corporation Information
Table 76. Novartis AG Description and Major Businesses
Table 77. Novartis AG Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Novartis AG Product
Table 79. Novartis AG Recent Development
Table 80. Roche Corporation Information
Table 81. Roche Description and Major Businesses
Table 82. Roche Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Roche Product
Table 84. Roche Recent Development
Table 85. Molecular Insight pharmaceuticals Corporation Information
Table 86. Molecular Insight pharmaceuticals Description and Major Businesses
Table 87. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Molecular Insight pharmaceuticals Product
Table 89. Molecular Insight pharmaceuticals Recent Development
Table 90. Callisto Pharmaceuticals Corporation Information
Table 91. Callisto Pharmaceuticals Description and Major Businesses
Table 92. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Callisto Pharmaceuticals Product
Table 94. Callisto Pharmaceuticals Recent Development
Table 95. Global Neuroendocrine Carcinoma Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 96. Global Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 97. Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 98. Global Neuroendocrine Carcinoma Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 99. North America: Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 100. North America: Neuroendocrine Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Europe: Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 102. Europe: Neuroendocrine Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Asia Pacific: Neuroendocrine Carcinoma Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 104. Asia Pacific: Neuroendocrine Carcinoma Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 105. Latin America: Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 106. Latin America: Neuroendocrine Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Middle East and Africa: Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 108. Middle East and Africa: Neuroendocrine Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 110. Key Challenges
Table 111. Market Risks
Table 112. Main Points Interviewed from Key Neuroendocrine Carcinoma Drugs Players
Table 113. Neuroendocrine Carcinoma Drugs Customers List
Table 114. Neuroendocrine Carcinoma Drugs Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroendocrine Carcinoma Drugs Product Picture
Figure 2. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Somatostatin Analogs Product Picture
Figure 4. Targeted Therapy Product Picture
Figure 5. Chemotherapy Product Picture
Figure 6. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Clinics
Figure 9. Oncology Centres
Figure 10. Ambulatory Surgery Centres
Figure 11. Neuroendocrine Carcinoma Drugs Report Years Considered
Figure 12. Global Neuroendocrine Carcinoma Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Neuroendocrine Carcinoma Drugs Sales 2015-2026 (K MT)
Figure 14. Global Neuroendocrine Carcinoma Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region in 2019
Figure 17. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Region in 2019
Figure 19. Global Neuroendocrine Carcinoma Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Drugs Revenue in 2019
Figure 21. Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type in 2019
Figure 24. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type in 2019
Figure 26. Global Neuroendocrine Carcinoma Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application in 2019
Figure 29. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application in 2019
Figure 31. North America Neuroendocrine Carcinoma Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 32. North America Neuroendocrine Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Country in 2019
Figure 34. North America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. U.S. Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 38. Canada Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Neuroendocrine Carcinoma Drugs Market Share by Type in 2019
Figure 40. North America Neuroendocrine Carcinoma Drugs Market Share by Application in 2019
Figure 41. Europe Neuroendocrine Carcinoma Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 42. Europe Neuroendocrine Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Country in 2019
Figure 44. Europe Neuroendocrine Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. Germany Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. France Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. U.K. Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Italy Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 54. Russia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Neuroendocrine Carcinoma Drugs Market Share by Type in 2019
Figure 56. Europe Neuroendocrine Carcinoma Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 58. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Market Share by Region in 2019
Figure 61. China Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. China Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. Japan Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. South Korea Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. India Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Australia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Taiwan Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Indonesia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Thailand Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Malaysia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Philippines Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 82. Vietnam Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Neuroendocrine Carcinoma Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Neuroendocrine Carcinoma Drugs Market Share by Application in 2019
Figure 85. Latin America Neuroendocrine Carcinoma Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 86. Latin America Neuroendocrine Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Mexico Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Brazil Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 94. Argentina Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Neuroendocrine Carcinoma Drugs Market Share by Type in 2019
Figure 96. Latin America Neuroendocrine Carcinoma Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 98. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Turkey Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. Saudi Arabia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Neuroendocrine Carcinoma Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 106. U.A.E Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Share by Application in 2019
Figure 109. North America Neuroendocrine Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. North America Neuroendocrine Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Neuroendocrine Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Europe Neuroendocrine Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Neuroendocrine Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Latin America Neuroendocrine Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
神経内分泌がんの世界市場（～2026年） Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the …- 腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …
- 神経内分泌機能検査の世界市場（～2026年） Neuroendocrine function test is a diagnosis process of finding out the neuroendocrine tumor. Based on treatment type, the global neuroendocrine function test market is segmented surgery and medication. As surgery is widely used in the neuroendocrine function test market. Similarly, based on end user…
- 基底細胞がん（BCC）治療薬の世界市場（～2026年） Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…
- 尿路上皮がん治療の世界市場（～2026年） Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar …